Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1649 1675
This examiner grants 34% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17784145 | COMPOSITIONS AND METHODS FOR TREATING NEUROMUSCULAR DISORDERS | Non-Final OA | The Regents of the University of California |
| 17194013 | Fascin-2 (FSCN2) Variants And Uses Thereof | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17790340 | LOOPED PROTEINS COMPRISING CELL PENETRATING PEPTIDES | Non-Final OA | Ohio State Innovation Foundation |
| 17995820 | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG | Non-Final OA | NOVARTIS AG |
| 17753635 | Management of conditions other than multiple sclerosis in ofatumumab-treated patients | Non-Final OA | Novartis AG |
| 17757955 | AGENT FOR PREVENTING OR TREATING ACUTE-PHASE NEUROMYELITIS OPTICA | Final Rejection | MITSUBISHI TANABE PHARMA CORPORATION |
| 18545688 | PAC1 ANTIBODIES AND USES THEREOF | Final Rejection | AMGEN INC. |
| 18168002 | COMBINATION THERAPY WITH SEMAPHORIN-4D BLOCKADE AND HTT-LOWERING AGENT FOR TREATMENT OF HUNTINGTON'S DISEASE | Non-Final OA | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. |
| 17908827 | Manipulating Glycogen in Alzheimer's Disease, Epilepsy, Traumatic Brain Injury, and ALS as a Treatment | Final Rejection | University of Kentucky Research Foundation |
| 17924461 | PEPTIDE USED TO PREVENT OR TREAT SYNUCLEINOPATHY | Non-Final OA | TOHOKU UNIVERSITY |
| 18611374 | APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF | Non-Final OA | Massachusetts Eye and Ear Infirmary |
| 17769705 | EXTRACELLULAR VESICLE-BASED AGENTS AND METHODS FOR THE TREATMENT OF NEUROPATHIC DISORDERS | Non-Final OA | University of Washington |
| 18011965 | PREVENTION OF AXONAL DAMAGE USING ANTIBODY BINDING TO AMYLOID BETA 1-42 | Non-Final OA | Eli Lilly and Company |
| 17883072 | Anti-CGRP Antibody Formulation | Final Rejection | Eli Lilly and Company |
| 17762543 | VACCINE THERAPY FOR RAN PROTEIN DISEASES | Final Rejection | University of Florida Research Foundation, Incorporated |
| 17509889 | Methods of Reducing Tau in Human Subjects | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18259141 | NON-BLOCKING HUMAN CCR8 BINDERS | Non-Final OA | VRIJE UNIVERSITEIT BRUSSEL |
| 17840368 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | Non-Final OA | Washington University |
| 16876353 | EFFICIENT, SCALABLE PRODUCTION OF HUMAN RETINAL PROGENITORS IN VITRO | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17794912 | DETERMINATION AGENT AND DETERMINATION METHOD FOR TAUOPATHY AND DEMENTIA-RELATED DISEASES | Non-Final OA | Sumitomo Pharma Co., Ltd. |
| 18183812 | FUSION PROTEIN COMPRISING A BLOOD-BRAIN BARRIER (BBB)-CROSSING SINGLE DOMAIN ANTIBODY FC5, AN IMMUNOGLOBULIN FC FRAGMENT AND A BETA-AMYLOID BINDING POLYPEPTIDE (ABP) | Non-Final OA | National Research Council of Canada |
| 18021566 | PROTEIN, POLYNUCLEOTIDE, VECTOR, HOST CELL, COMPOSITION, METHOD FOR TREATING AN ILLNESS, IN-VITRO METHOD FOR PREDICTING MULTIPLE SCLEROSIS, AND USE OF A PROTEIN OR COMPOSITION | Non-Final OA | Fundação Oswaldo Cruz |
| 18110960 | METHOD AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS | Non-Final OA | RAMOT AT TEL AVIV UNIVERSITY LTD. |
| 18346691 | PROCESS FOR ESTABLISHING A HUMAN TESTICULAR TISSUE CULTURE SYSTEM | Final Rejection | PATERNA BIOSCIENCES INC. |
| 18003768 | PEPTIDES AND USES THEREOF | Non-Final OA | PreveCeutical Medical Inc. |
| 17923456 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | Non-Final OA | Annexon, Inc. |
| 18038065 | PHARMACEUTICAL COMPOSITION COMPRISING INSOLUBLE CAMPTOTHECIN COMPOUND-CONTAINING NANOPARTICLE FOR TREATMENT OF CANCER AND COMBINATION THERAPY THEREOF | Non-Final OA | SNBioScience Inc. |
| 17596622 | USE OF SRRD IN THE INHIBITION OF PROTEIN AGGREGATION | Final Rejection | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18147287 | METHODS OF TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER | Final Rejection | Viela Bio, Inc. |
| 16606605 | IMMUNOGLOBULIN PRODUCTS FOR USE IN THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY | Final Rejection | CSL BEHRING AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy